
price close busi august
orasur domin provid saliva collect
devic genet test leader oral fluid
diagnost rapid point care hiv hcv test
diagnost tool
challeng day ahead lower
price target stick hold rate
last week privileg host ceo steve tang cfo roberto
cuca firesid chat annual canaccord genuiti growth confer
key focu discuss center molecular collect genom ancestri
microbiom busi miss our/street estim guid
street lower revenue guid detail hold thesi
pleas see recent downgrad stock unfortun ancestry-dtc
market ancestri declin still meaning portion
revenu profit see pocket growth
microbiom mdx collect ex-ancestri busi double-digit
declin unclear turnaround stick hold rate
lower pt
busi declin revenu declin driven
y/i declin royalti incom ancestri declin molecular collect
system includ declin genom molecular collect system
declin infecti diseas test includ global hiv rev
declin hcv test
busi grow indic expect doubl digit growth
microbiom busi rev genom revenu exclud one larg
genom custom estim rev also expect double-digit growth
global hiv test busi driven hiv self-test busi though visibl
limit requir ngo entiti africa help ramp order
impli guid impli guid call rev
midpoint q/q growth driven q/q growth averag
last three year said anoth way expect bring
revenu full year major spike may difficult achiev
lower guid midpoint lower full year revenue guid
prior
cite soft dtc test lower expect payment ancestri
guid initi weak revenue guid y/i
far prior initi ep guid
prior
recap rev y/i miss
due miss royalti payment y/i ancestri us hiv
ou revenu y/i hiv self-test order slip ep
beat our/street gm beat due higher mix order
smaller custom earn volume-bas price concess
expir royalti pay hiv self-test devic total molecular
collect product rev y/i though
skeptic recoveri dtc test caution
extend
lower revenue estim page model commentari
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
lower pt updat thesi new price target lower
use multipl revenu estim formerli
discount back two year discount rate dilut share
outstand ad net cash posit balanc
sheet formerli pt use multipl revenu estim
discount back year plu net cash reiter
hold rate assign lower multipl stock given declin top
line weak guid tough spike-up requir hit lower
guid could wrong sign larg hcv partnership
countrywid erad ou realiz big comeback hiv self-test order
unexpect recoveri dtc ancestri test busi could
happen assum ancestri resum heavi market kit discount
consum around holiday
model chang factor revenu miss weak guid lower
revenu estim help gm beat
rais gm estim bump
ep estim lower revenu
estim lower revenu estim
go ancestri know labcorp
result dtc test relat ancestri test pressur
expect grow year tri specul reason
high level think enough clue believ
like undergo technolog transfer array genotyp sequenc part
overcom doubt clinic util lack therefor array genotyp
mean think growth might recov day
visibl think could multi-year transit
stock price cover compani mention
laboratori corpor america hold lh nyse hold
hold unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price august
diagnost tool
hold unchang target price august
diagnost tool
hold unchang target price august
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin august et
date time product august et
price target use multipl revenu estim discount back two year discount rate
dilut share outstand ad net cash posit balanc sheet
price target appli multipl adj ep estim
laboratori corpor america hold lh
pt use multipl adj ep estim
risk achiev target price valuat
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
hold unchang target price august
diagnost tool
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
